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The association between minor mutations in human immu-
nodeficiency virus (HIV) protease at baseline and development
of common primary mutation 90M at virological failure (con-
ferring some resistance to all protease inhibitors [PIs]) was
evaluated in 93 previously drug-naive patients experiencing
failure of their first PI-based antiretroviral regimens. In logistic
regression analysis, the probability of accumulating a new 90M
mutation at virological failure was associated with the presence
at baseline of minor mutation 36I (naturally occurring in
∼25% of HIV clade B and in 180% of HIV non-clade-B viruses)
(adjusted odds ratio, 13.5 [95% confidence interval, 1.89–95.6];
) and, possibly, of 10I/V. This suggests a potential rolePp .009
for the presence of 36I at baseline in predicting the appearance
of 90M at virological failure.
Experimental and clinical evidence supports the use of drug-
resistance testing in HIV-infected patients receiving therapy and
experiencing virological failure [1–4]. In contrast, no similar
evidence is yet available for patients with long-term infections
who are about to initiate their first antiretroviral therapy reg-
imens (chronically infected, drug-naive patients).
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The limited rate of primary mutations present in chronically
infected, drug-naive patients may account, in part, for this lack
of evidence [5, 6]. With regard to secondary mutations, their
correlation with therapeutic outcome is still unclear, but a re-
cent paper from our group has shown that the secondary mu-
tation 36I in the protease (alone or with 10I/V) is associated
with an increased risk of virological failure of highly active an-
tiretroviral therapy (HAART) regimens containing a protease
inhibitor (PI) [7].
Secondary mutations are often present, as common poly-
morphisms, in HIV protease of drug-naive patients. They may
favor the appearance of primary mutations, such as 90M, which
are present in ∼40%–50% of patients experiencing multiple
virological failures, and are associated with different levels of
resistance to all PIs currently in use [8, 9]. This mutation may
remain in the viral genome after interruption of a PI-containing
regimen, probably because of the relatively high fitness of virus
strains containing 90M that is associated with specific secondary
mutations [10]. Drug resistance and persistence of the mutation
may thus affect future therapeutic attempts and may disrupt
strategies based on rotation of drugs belonging to the same
class, even after periods of interruption of the PI-containing
regimen. For these reasons, the identification of factors favoring
the appearance of 90M in the protease is particularly relevant
from the clinical standpoint. The aim of the present study was
therefore to test whether specific minor mutations present in
HIV protease before initiation of a PI-containing HAART reg-
imen correlate with the appearance of 90M at the time of vi-
rological failure.
Patients, materials, and methods. One hundred ninety-
three patients belonging to the Italian Cohort Naive Antiret-
rovirals [11] initiated a first antiviral regimen including exactly
1 PI and 2 nucleoside reverse-transcriptase inhibitors (NRTIs)
and subsequently experienced virological failure, defined as the
time of the first of 2 consecutive determinations of virus levels
1500 copies/mL after 24 weeks of therapy. All these patients
had a genotypic test performed on a sample stored before in-
itiation of therapy. For 93 of these patients, another plasma
sample, stored between 2 weeks before and 6 weeks after the
date of defined virological failure, was also available to be tested
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for genotypic resistance. Characteristics of these 93 patients were
similar to those of the remaining 100 patients (for whom plasma
samples were not available), in terms of proportion of males
( ), mode of transmission ( ), Centers for DiseasePp .11 Pp .40
Control and Prevention (CDC) stage ( ), presence of 10I/Pp .48
V ( ) or 36I ( ) before initiation of HAART, me-Pp .50 Pp .34
dian age ( ), median pre-HAART CD4 cell count (Pp .07 Pp
), and median virus load change from baseline ( )..96 Pp .09
Viral RNA was extracted from 500 mL of each plasma sample
by use of the QiaAmp Viral RNA kit (Qiagen) and was retro-
transcribed by use of reverse-transcriptase (RT) polymerase chain
reaction (Viroseq 2; APPLERA). Protease and the first 340 aa of
RT were sequenced by use of an ABI PRISM dye terminator
cycle in a capillary-automated DNA sequencer (ABI-3100; both
Applied Biosystems), in accordance with a well-standardized
method [5, 7]. Mutations considered in the present study are
those reported in the most recent update of the International
AIDS Society–USA table of mutations [10]. A mutation was
defined as “new” if detected at the time of virological failure but
not at baseline.
The end point was the probability of having accumulated a
new 90M mutation at the time of virological failure. The pro-
portions of patients with 90M at the time of virological failure,
according to baseline characteristics, were compared, and dif-
ferences were tested by use of a x2 statistic.
A multivariable logistic regression analysis was used to identify
factors associated with this end point [12]. The following co-
variates have been considered: sex, age, modality of HIV trans-
mission, CD4 cell count nadir, pretherapy virus load, preexisting
mutations in the protease regions (i.e., 10I/V, 36I, 63P, and 77I),
and each drug initiated. For the pretherapy virus load, 2 binary
variables were considered by use of the arbitrary, a priori–chosen
cut-off values of 1 log10 and 1.5 log10 copies/mL. The analysis
was performed in accordance with an intention-to-treat prin-
ciple, by ignoring treatment switches. A sensitivity analysis, in
which patients who changed treatment before resistance testing
were instead excluded, was also performed.
Results. The baseline characteristics of the 93 HIV-infected
patients included in the present study were the following: median
HIV RNA level at baseline was 108,705 copies/mL (interquartile
range [IQR], 48,000–280,000 copies/mL); 49 patients (52.7%)
had 1100,000 HIV RNA copies/mL. Median CD4 cell count was
265 cells/mL (IQR, 83–453 cells/mL); 36 patients (38.7%) had a
CD4 cell count !200 cells/mL at baseline; 18 patients (19.4%)
were in stage C, according to CDC 1993 classifications [13].
Zidovudine (79.6%) and lamivudine (57.0%) were the NRTIs
most represented in the first HAART regimens. Hard gel (HG)–
saquinavir and indinavir (always administered 3 times daily in
an unboosted regimen) were the most used PIs in the initial
regimen (50.5% and 31.2%, respectively). Overall, the most
frequent combination regimens were zidovudine plus lamivu-
dine plus indinavir ( ; 22.6%), zidovudine plus lamivu-np 21
dine plus HG-saquinavir ( ; 20.4%), and zidovudine plusnp 19
zalcitabine plus HG-saquinavir ( ; 12.9%).np 12
At baseline, 18 patients (19.4%) harbored a completely wild-
type (wt) virus in both the RT and the protease regions. Three
patients (3.2%) harbored mutations only in the RT region, 68
(73.1%) only in the protease region, and 4 (4.3%) in both the
RT and the protease regions. Of 7 patients with RT mutations,
6 harbored 1 of the following: 70R, 106A, 118I ( patients),np 2
184V, or 210W; 1 harbored both 41L and 215Y.
Only 1 of 93 patients harbored a major mutation (46L) in the
protease region at baseline; among minor mutations (or poly-
morphisms), 63P was found in 46 patients (49.5%), 36I and 77I
in 23 patients each (24.7%), 10I and 71T in 5 patients each
(5.4%), 10V in 4 patients (4.3%), and 33F in 2 patients (2.2%);
20R, 53L, and 671V were found in 1 patient each (1.1%). Thirty-
five patients showed 11 mutation in the protease region.
Virological failure occurred a median of 40 weeks (range, 24–
154 week) after the initiation of HAART. The median HIV RNA
level at the time of virological failure was 3.65 log10 copies/mL
(IQR, 3.18–4.32 log10 copies/mL), and the median CD4 cell count
was 390 cells/mL (IQR, 178–593 cells/mL). Median time from
baseline to the date of the second genotypic test was 48 weeks
(range, 21–152 weeks); 34 patients (36.6%) had modified their
regimen before the second genotypic test, but, at the time of the
test, they were all still receiving a PI-containing HAART regimen.
Plasma samples sequenced at the time of virological failure
showed 76 new mutations in the RT region (occurring in 56
patients), and 72 new mutations in the protease region (oc-
curring in 37 patients) (table 1). Overall, at the time of viro-
logical failure, 25 patients (26.9%) had both new RT and pro-
tease mutations, 31 (33.3%) had only new RT mutations, 12
(12.9%) had only new protease mutations, and 25 (26.9%) had
no new RT or protease mutations. The most frequent new RT
mutation was 184V, which occurred in 42 patients (all treated
with lamivudine-containing regimens). With regard to the pro-
tease region, the most frequent new protease mutation was
90M, which occurred in 13 patients and was associated with
other new mutations in 11 of 13 patients. Mutation 90M ap-
peared in 3 (33.3%) of 9 patients carrying 10I/V at baseline
and in 10 (11.9%) of 84 patients not carrying the mutation
( , x2 test); similarly, 90M appeared in 6 (26.1%) of 23Pp .08
patients carrying 36I at baseline and in 7 (10%) of 70 patients
not carrying the mutation ( , x2 test). Of interest, thePp .05
frequency of 90M was greater than that for all new minor
mutations occurring at the time of virological failure (table 1).
Table 2 shows the crude and adjusted odds ratios (ORs) of
having the 90M mutation at the time of virological failure, by
logistic regression analysis. In this model, the presence of either
10I/V or 36I before initiation of HAART was significantly as-
sociated with the risk of developing 90M, after adjusting for
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Table 1. New mutations appearing in the
reverse transcriptase (RT) and protease
regions of HIV-1, harbored by 93 patients at
the time of virological failure.




































CD4 cell count nadir, pretherapy virus load, and number of
other mutations in the RT and protease regions (for the pres-
ence of 10I/V: adjusted OR, 9.11 [95% confidence interval [CI],
1.09–76.10]; and for the presence of 36I: adjusted OR,Pp .04
13.5 [95% CI, 1.89–95.6]; ). This effect does not ap-Pp .009
pear to be shared with other minor protease mutations, since
natural polymorphisms 63P and 77I, with prevalences similar
to or even greater than that of 36I at baseline, failed to be
associated with the appearance of 90M (table 2). Results of this
analysis remained similar (1) after excluding 1 patient carrying
a non-clade-B strain of HIV (adjusted OR between 10I/V and
90M, 10.04 [95% CI, 1.55–139.07]; , and adjusted ORPp .03
between 36I and 90M, 12.96 [95% CI, 1.89–89.08]; ),Pp .009
(2) after excluding 7 patients who carried RT mutations at base-
line (adjusted OR between 10I/V and 90M, 13.28 [95% CI, 1.55–
114.06]; , and adjusted OR between 36I and 90M, 11.58Pp .02
[95% CI, 1.71–78.61]; ), and (3) after adjusting for thePp .01
use of HG-saquinavir over the course of the follow-up (adjusted
OR between 10I/V and 90M, 13.74 [95% CI, 1.44–131.52];
, and adjusted OR between 36I and 90M, 14.01 [95%Pp .02
CI, 1.76–111.22]; , significant at the Bonferroni-correctedPp .01
level).
Discussion. The results of the present report show a sig-
nificant correlation between the presence of minor mutations
36I and 10I/V in HIV protease before initiation of HAART and
the appearance of 90M at the time of virological failure. The
strength of the association was greater for the presence of 36I
(significant also, at a conservative Bonferroni-corrected value
of , on the basis of the 4 mutations tested: 10I/V, 36I,Pp .0125
63P, and 77I). These results are in line with those reported in
our previous report, showing a greater risk of virological failure
in patients carrying mutation 36I (alone or associated with
mutations at codon 10) at baseline, but not other natural pro-
tease polymorphisms [7].
Of interest, the multivariable analysis showed that the ap-
pearance of 90M was significantly more frequent in patients
whose virus load at the time of virological failure was 11.4
log10 copies/mL lower than pretherapy levels, compared with
patients whose virus load either had decreased 11.4 log10 copies/
mL or had a small or no decrease (table 2). This indicates that
partial virus suppression, rather than either major or no sup-
pression, may have increased the risk of appearance of 90M.
This also indirectly suggests that drug pressure on a highly
replicating virus is necessary to select for resistant mutations;
in contrast, low drug pressure (because of poor adherence to
the treatment regimen or limited drug absorption) decreases
the chances of developing resistance, as the wt virus will be the
best replicating virus. Whether this also applies to the data
described in this report requires a direct measure of adherence,
which is not available for these 93 patients.
The interpretation of our results potentially may be limited
by some factors. First, statistical analysis was performed by an
intention-to-treat approach that ignores therapy switches. How-
ever, when the same analysis was performed after excluding
patients who changed the initial HAART regimen, the associ-
ation between 36I and the appearance of 90M at the time of
virological failure remained similar (data not shown). Second,
these results cannot be extended, in principle, to all PIs cur-
rently in use or to ritonavir-boosted PIs (widely used nowa-
days). Indeed, a large proportion of patients in our cohort were
treated with HG-saquinavir (the most frequently used PI at the
1986 • JID 2004:189 (1 June) • BRIEF REPORT
Table 2. Crude and adjusted odds ratios (ORs) of acquiring 90M at the time of virological failure,
by logistic regression model (intention-to-treat analysis; switches in therapy were ignored).
Covariate
Crude analysis Adjusted analysisa
OR (95% CI) P OR (95% CI) P
Baseline CD4 cell count, per 100 cells/mL higher 0.93 (0.71–1.22) .60 0.95 (0.69–.130) .75
Virus load change, log10 copies/mL
!1 log decrease or an increase 1.00
1–1.4 log decrease 4.13 (0.91–18.7) .07 15.5 (1.64–146.8) .02
1.5 log decrease 1.42 (0.29–6.86) .66 1.54 (0.23–10.5) .65
10I/V
No 1.00 1.00
Yes 3.70 (0.80–17.2) .09 9.11 (1.09–76.1) .04
36I
No 1.00 1.00
Yes 3.18 (0.94–10.7) .06 13.5 (1.89–95.6) .009
63P
No 1.00 1.00
Yes 1.23 (0.38–3.97) .73 1.21 (0.29–5.07) .80
77I
No 1.00 1.00
Yes 0.51 (0.11–2.50) .41 0.87 (0.11–6.72) .89
Other protease mutations
1 additional 0.48 (0.06–3.63) .48 0.99 (0.13–7.42) .99
NOTE. Bold type indicates significant values. CI, confidence interval.
a Adjusted for the factors shown in this table.
time of enrolment in the present study [1997–1999]), a drug
with poor gut absorption that is therefore more prone to induce
a limited pressure on the virus [14]. Indeed, our data show
that the effect of having preexisting 36I (but not 10I/V) on the
chance of developing 90M was somewhat lower in patients
receiving HG-saquinavir (OR, 1.08 [95% CI, 0.23–5.08]) than
in patients receiving other PIs (OR, 22.20 [95% CI, 1.92–
256.82]; , test for interaction).Pp .05
Mutation 36I is a natural polymorphism present in 180% of
patients infected with non-clade-B strains of HIV [15]. Of in-
terest, recent evidence shows that, in patients treated with nel-
finavir-containing regimens, clade-G strains tend to evolve to-
ward mutation 90M, rather than 30N (the latter is typically found
in patients infected with clade B strains of HIV at the time of
the first virological failure) [16]. Studies of large cohorts of pa-
tients that are able to discriminate among different non-clade-
B strains of HIV and that use different PIs are now mandatory
to clarify whether 36I and other common polymorphisms affect
PI-containing first-line HIV therapies in poor-resource countries,
where circulating strains belong mainly to clades other than B.
In conclusion, these findings strongly suggest, for the first
time, an association between specific polymorphisms and the
appearance of a primary mutation in vivo (which is, in turn,
strongly related to virological failure). This has obvious practical
implications. Resistance tests performed before the initiation
of the first PI-containing regimens may help to identify those
patients who may be more prone to virological failure of such
regimens because they are carrying a virus already harboring
certain mutations. In other words, the genetic barrier for PI is
lowered by the presence of such mutations, as the virus would
need a smaller number of “mutational steps” to overcome the
inhibition of the drugs. Further clinical studies are warranted,
to confirm this hypothesis and to verify whether it holds true
for some PIs more than for others. If so, the use of resistance
testing in chronically infected, drug-naive patients before ini-
tiation of therapy should become the rule.
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